• 1
    Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Laboratory Sci 2000; 30: 321
  • 2
    Masferrer JL, Leahy KM, Koki AT et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 130611
  • 3
    Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001; 22: 1725
  • 4
    Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164: 8205
  • 5
    Soslow RA, Dannenberg AJ, Rush D et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 263745
  • 6
    Sheng H, Shao J, Kirkland SC et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 22549
  • 7
    Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6: 1358
  • 8
    Marrogi AJ, Travis WD, Welsh JA et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 473944
  • 9
    Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000; 7: 116370
  • 10
    Tomozawa S, Tsuno NH, Sunami E et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83: 3248
  • 11
    Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 194652
  • 12
    Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 2000; 42: 73
  • 13
    Eastham JA, Mire E, Williams BJ. Cyclooxygenase-2 (COX-2) expression in primary and metastatic prostate cancer. J Urol 2000; 163 (Suppl. 4): 104 (A453)
  • 14
    Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 4245
  • 15
    Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in prostate cancer cells independently of bcl-2. J Biol Chem 2000; 275: 11397
  • 16
    Pruthi RS, Johnstone I, Tu I-P, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy. Correlation with histologic characteristics of the primary cancer. Urology 1997; 49: 73742
  • 17
    Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System, 2nd edn. Cary, NC: SAS Institute Inc, 2000
  • 18
    Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 18507
  • 19
    Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 18215
  • 20
    Shipley WU, Thames HD, Sandler HM et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 1598604
  • 21
    Ferrigni RG, Schild SE. The evaluation and treatment of biochemical failure following radical prostatectomy. AUA Update Series 1999; 18: 2427